List view / Grid view
Researchers at Tokyo University of Science have identified three new enzyme families that degrade the complex bacterial carbohydrate β-1,2-glucan – offering new opportunities for enzyme engineering.
Genomics laid the foundation for precision medicine, but on its own, it offers only part of the picture. This article explores how integrated multiomics can provide the deeper biological context needed to drive more effective therapies forwards.
What if you could actually see where a drug travels in the body down to the cellular level. Find out how mass spectrometry imaging (MSI) is making that possible – reshaping drug development from the inside out.
Drug development has long been hindered by fragmented data and complex processes, but a new wave of AI is reshaping the landscape. By integrating genomic, clinical and molecular data, multimodal models are revealing hidden patterns and accelerating more precise advancements in medicine.
A new study from Central South University reveals how adenosine phosphate signalling shapes the tumour microenvironment in melanoma, offering a new biomarker for guiding personalised cancer treatment.
The world’s first translational research center dedicated to urea cycle disorders (UCDs) has been launched in Zürich, marking a significant moment in rare disease innovation.
ELRIG has announced the keynote speakers for Drug Discovery 2025, its flagship life sciences event taking place in Liverpool, England this October.
K Navigator, a new AI-powered research co-pilot, is set to transform biomedical science by helping researchers explore complex data and accelerate discoveries.
Scientists have identified protein tyrosine phosphatase delta (PTPRD) as a key regulator of liver metabolism, offering a potential new drug target for treating metabolic liver diseases like MASLD and MASH.
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has partnered with Rarity Bioscience to introduce a groundbreaking approach to oncology research.
Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
Cornell researchers have discovered how transposons, or 'jumping genes,' insert themselves into bacterial chromosome ends, potentially transforming genetic engineering and advancing biotechnology. This breakthrough could reshape antibiotic research and unlock new drug discoveries.
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
